I-PBAC liqumrhu leengcaphephe elizimeleyo eliqeshwe nguRhulumente wase-Australia. Amalungu abandakanya oogqirha, iingcali zempilo, i-economists yezempilo kunye nabameli babathengi.
Indima yabo kukucebisa amayeza amatsha ukuba afakwe kuluhlu lwenkqubo yezibonelelo zoxubo mayeza (pharmaceutical benefit scheme (PBS). Akukho mayeza amatsha anokufakwa kuluhlu ngaphandle kokuba ikomiti yenza izindululo ezilungileyo. I-PBAC idibana kathathu ngonyaka, ngokwesiqhelo ngoMatshi, ngoJulayi nangoNovemba.
Kweli phepha:
I-ajenda yentlanganiso ye-PBAC ezayo:
Novemba 2020
Ukuhanjiswa kweLymphoma kunye ne-CLL kwi-ajenda ezayo
NgoNovemba 2020 ukuhanjiswa kwe-lymphoma/CLL kwi-ajenda
| Uhlobo lokungeniswa | Igama leziyobisi kunye nomxhasi | Uhlobo lweziyobisi kunye nokusetyenziswa | Uluhlu olucelwe ngumxhasi & nenjongo |
| Uluhlu olutsha (ungeniso olungephi) | Ibrutinib | I-lymphocytic leukemia engapheliyo (CLL); I-lymphocytic lymphoma encinci (SLL); Ingubo yeeseli lymphoma | Ukucela isigunyaziso Uluhlu olufunekayo lwethebhulethi ye-ibrutinib phantsi kweemeko ezifanayo njenge-capsule esele idwelisiwe. |
| Uluhlu olutsha (ungeniso olungephi) | Mogamulizumab (Kyowa Kirin) | I-Cutaneous T-cell lymphoma (CTCL) | Ukungeniswa kwakhona ukuze kucelwe iCandelo le-100 (inkxaso-mali esebenzayo ye-chemotherapy) Igunya elifunekayo uluhlu lwezigulane ezine-CTCL ebuyela umva okanye i-refractory ezakhe zanyangwa ubuncinane ngonyango olunye lwangaphambili. |
Iziphumo zentlanganiso ye-PBAC
July 2020
Ukuhanjiswa kweLymphoma kunye ne-CLL kunye neziphumo
NgoJulayi 2020 iziphumo zentlanganiso ye-PBAC yokungeniswa kwe-lymphoma kunye ne-CLL
| Iziyobisi, umxhasi, uhlobo lokungeniswa | Uhlobo lweziyobisi okanye ukusetyenziswa | Uluhlu olucelwe ngumxhasi/injongo yokungeniswa | Iziphumo ze-PMAC |
Ukunyanga (AbbVie) Guqula kuluhlu (ungeniso olungephi) | I-Cronic lymphocytic leukemia (CLL) | Ukungeniswa kwakhona ukucela uluhlu olufunekayo lweGunya, ngokudityaniswa ne-Obinutuzumab, kunyango lokuqala lwezigulane ezine-CLL ezineemeko ezihlalayo ze-fludarabine esekelwe kwichemotherapy. | I-PBAC icebise ukudweliswa kwe-venetoclax kudityaniswe ne-obinutuzumab kunyango lodidi lokuqala lwezigulane ezine-CLL ezineemeko ezihlala zihleli kunye nezingafanelekanga kwi-fludarabine esekelwe kwi-chemo- immunotherapy. |
| I-Acalabrutinib (AstraZeneca) | I-Cronic lymphocytic leukemia (CLL) okanye i-lymphocytic lymphoma encinci (SLL) | Ukucela iGunya elifunekayo uluhlu lonyango lwezigulane (mhlawumbi njenge-monotherapy okanye ngokudibanisa ne-obinutuzumab) kunye ne-CLL engazange inyangwe okanye i-SLL ithathwa njengengafanelekanga kunyango nge-analogue ye-purine. Isicelo sesibini sasisetyenziselwa kuphela kwi-subgroup yezigulane ezinokususwa kwe-17p. | I-PBAC ayizange cebisa uluhlu lwe-acalabrutinib, ukusetyenziswa njenge-monotherapy okanye ngokudibanisa ne-obinutuzumab, kunyango lokuqala lwezigulane ezine-CLL okanye i-SLL ezithathwa njengezingafanelekanga unyango nge-analogue ye-purine. I-PBAC ithathele ingqalelo ukuba umlinganiselo wokonyuka kweendleko zokusebenza kakuhle wawuphezulu ngendlela engamkelekanga kwaye awuqinisekanga ngexabiso elicetywayo. |
Mogamulizumab (Kyowa Kirin) | I-Cutaneous T-cell lymphoma (CTCL) | Ukucela iCandelo le-100 (iNkxaso-mali eLungileyo yoNyango lweKhemo) iGunya eliFunwayo (eliBhalileyo) kwizigulana ezine-CTCL ebuyela umva okanye i-refractory eziye zanyangwa ngaphambili ngonyango olunye ubuncinane lwangaphambili. | I-PBAC ayizange iphakamise ukufakwa kuluhlu lwe-mogamulizumab kunyango lwezigulane ezine-CTCL ebuyela emva okanye e-refractory elandela ubuncinane unyango lwenkqubo enye yangaphambili kule meko. I-PBAC ithathele ingqalelo ukuba ubungakanani benzuzo ye-mogamulizumab ngokwenkqubela phambili yokusinda simahla kunye nokusinda ngokubanzi bekungaqinisekanga. Ukongeza, i-PBAC ithathele ingqalelo umlinganiselo wokunyuka kweendleko zokusebenza kakuhle ngokungamkelekanga kwaye ungaqinisekanga ngexabiso elicetywayo, kwaye impembelelo yemali eqikelelweyo ibingaqinisekanga. |
NgoMatshi 2020 i-ajenda yentlanganiso ye-PBAC ye-lymphoma/CLL kunye nokulinda okugqwesileyo kokulinda inyathelo ukusuka ngoNovemba ka-2019
| Igama leziyobisi kunye nomxhasi | Udidi olusezantsi | Uluhlu oluceliweyo kunye nenjongo | Isiphumo se-PBAC |
| Ibrutinib (Janssen) | I-Cronic lymphocytic leukemia (CLL) okanye i-lymphocytic lymphoma encinci (SLL) | Ukungeniswa kwakhona ukucela imbuyekezo ye-PBS yonyango lwe-CLL okanye i-SLL kunye nobungqina bokususwa kwechromosome enye okanye ngaphezulu kwe-17p | I-PBAC icebise uluhlu lwe-PBS lwe-ibrutinib kunyango lokuqala kunye ne-CLL/SLL ngokucima i-17p -isalinde ukudweliswa, ukusukela ngoNovemba ka-2019 |
| I-Acalabrutinib (AstraZeneca) | I-Cronic lymphocytic leukemia (CLL) okanye i-lymphocytic lymphoma encinci (SLL) | Ukucela uluhlu lwe-PBS kunyango lwezigulane ezine-CLL ezibuyela umva okanye i-refractory okanye i-SLL engafanelekanga unyango nge-analogue ye-purine | I-PBAC icebise uluhlu lwe-acalabrutinib kunyango lwezigulane ezine-R/R CLL/SLL kunyango lomgca wesibini – ilinde ukudweliswa kwePBS ukusukela ngoMatshi ka-2020 |
| I-Pembrolizumab (MSD) | I-Primary mediastinal B-cell lymphoma (PMBCL) | Ukungeniswa kwakhona ukucela uluhlu lwe-PBS kunyango lwe-PMBCL ebuyiselweyo okanye echasayo | I-PBAC icebise ngoluhlu lwe-PBS lwe-pembrolizumab ye-R/R PMBCL – wilindele ukudweliswa kwePBS ukusukela ngoMatshi ka-2020 |
